Page 114 - Read Online

Kotecha et al. J Cancer Metastasis Treat 2021;7:67 https://dx.doi.org/10.20517/2394-4722.2021.163 Page 11 of 11

39. Choueiri TK, Bauer TM, Mcdermott DF, et al. Phase 2 study of the oral hypoxia-inducible factor 2α (HIF-2α) inhibitor MK-6482 in
combination with cabozantinib in patients with advanced clear cell renal cell carcinoma (ccRCC). J Clin Oncol 2021;39:272. DOI
40. Charych DH, Hoch U, Langowski JL, et al. NKTR-214, an engineered cytokine with biased IL2 receptor binding, increased tumor
exposure, and marked efficacy in mouse tumor models. Clin Cancer Res 2016;22:680-90. DOI PubMed
41. Diab A, Tannir NM, Bentebibel SE, et al. Bempegaldesleukin (NKTR-214) plus nivolumab in patients with advanced solid tumors:
phase I dose-escalation study of safety, efficacy, and immune activation (PIVOT-02). Cancer Discov 2020;10:1158-73. DOI PubMed
42. Tannir NM, Agarwal N, Pal SK, et al. A phase III randomized open label study comparing bempegaldesleukin (NKTR-214) plus
nivolumab to sunitinib or cabozantinib (investigator's choice) in patients with previously untreated advanced renal cell carcinoma. J
Clin Oncol 2019;37:TPS4595. DOI
43. Dovedi SJ, Elder MJ, Yang C, et al. Design and efficacy of a monovalent bispecific PD-1/CTLA4 antibody that enhances CTLA4
+
blockade on PD-1 activated T cells. Cancer Discov 2021;11:1100-17. DOI PubMed